Life for journal editors, reviewers and authors of academic papers runs a significant chance of changing irreversibly in the coming months. It appears we are more responsible for what is published than we may think. Pacira BioSciences Inc., a pharmaceutical company, has brought a trade libel action in the US District of New Jersey against the journal Anesthesiology, its Editor-in-Chief, the American Society of Anesthesiologists and multiple authors of several published papers, for statements made about a non-opioid pain medication drug manufactured by Pacira [1]. The Complaint and Demand for Jury Trial is well worth reading, not just because the analgesic in question has been used in orthopaedic surgery, but that statements made by authors can be challenged, and may even be presented to a jury. Each of us must be certain we are accurate and able to justify everything we say or publish. I do not know if this case will proceed but its mere existence is a wake-up call for journals.

中文翻译：

---

你比你意识到的更有责任感


未来几个月，期刊编辑、审稿人和学术论文作者的生活很有可能发生不可逆转的变化。看来我们对所发表的内容负有比我们想象的更多的责任。制药公司 Pacira BioSciences Inc. 在美国新泽西州地区对《麻醉学》杂志、其主编、美国麻醉医师协会以及多篇已发表论文的多名作者提起贸易诽谤诉讼，原因是其发表的言论关于 Pacira 生产的一种非阿片类止痛药物 [1]。 《陪审团审判的投诉和要求》非常值得一读，不仅因为有问题的镇痛药已用于骨科手术，而且作者的陈述可能会受到质疑，甚至可能会提交给陪审团。我们每个人都必须确保我们所说或发布的一切都是准确的，并且能够证明我们所说或发布的一切都是合理的。我不知道这个案子是否会继续下去，但它的存在本身就是对期刊的一个警钟。